

Steven Stone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/771542/publications.pdf>

Version: 2024-02-01

44
papers

7,529
citations

566801

15
h-index

454577

30
g-index

44
all docs

44
docs citations

44
times ranked

7983
citing authors

#	ARTICLE	IF	CITATIONS
1	A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. <i>Science</i> , 1994, 266, 66-71.	6.0	5,747
2	Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. <i>Lancet Oncology</i> , The, 2011, 12, 245-255.	5.1	668
3	Validation of a Cell-Cycle Progression Gene Panel to Improve Risk Stratification in a Contemporary Prostatectomy Cohort. <i>Journal of Clinical Oncology</i> , 2013, 31, 1428-1434.	0.8	323
4	Prognostic Utility of the Cell Cycle Progression Score Generated from Biopsy in Men Treated with Prostatectomy. <i>Journal of Urology</i> , 2014, 192, 409-414.	0.2	180
5	A Major Predisposition Locus for Severe Obesity, at 4p15-p14. <i>American Journal of Human Genetics</i> , 2002, 70, 1459-1468.	2.6	133
6	TBC1D1 is a candidate for a severe obesity gene and evidence for a gene/gene interaction in obesity predisposition. <i>Human Molecular Genetics</i> , 2006, 15, 2709-2720.	1.4	129
7	A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma. <i>European Urology</i> , 2018, 73, 763-769.	0.9	63
8	Linkage of body mass index to chromosome 20 in Utah pedigrees. <i>Human Genetics</i> , 2001, 109, 279-285.	1.8	51
9	Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance. <i>BJU International</i> , 2017, 120, 808-814.	1.3	48
10	Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 102-107.	2.0	26
11	Comparison of cell cycle progression score with two immunohistochemical markers (PTEN and Ki-67) for predicting outcome in prostate cancer after radical prostatectomy. <i>World Journal of Urology</i> , 2018, 36, 1495-1500.	1.2	25
12	Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized Prostate Cancer. <i>European Urology</i> , 2019, 75, 515-522.	0.9	22
13	Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 310.e7-310.e13.	0.8	19
14	Cell cycle progression score predicts metastatic progression of clear cell renal cell carcinoma after resection. <i>Cancer Biomarkers</i> , 2015, 15, 861-867.	0.8	17
15	Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence. <i>Cancer Biomarkers</i> , 2016, 17, 83-88.	0.8	15
16	Biopsy Cell Cycle Proliferation Score Predicts Adverse Surgical Pathology in Localized Renal Cell Carcinoma. <i>European Urology</i> , 2020, 78, 657-660.	0.9	10
17	Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score. <i>Personalized Medicine</i> , 2019, 16, 491-499.	0.8	9
18	The clinical cell-cycle risk (CCR) score is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, , .	0.4	9

#	ARTICLE	IF	CITATIONS
19	Extracapsular extension on MRI indicates a more aggressive cell cycle progression genotype of prostate cancer. <i>Abdominal Radiology</i> , 2019, 44, 2864-2873.	1.0	8
20	Personalizing Localized Prostate Cancer: Validation of a Combined Clinical Cell-cycle Risk (CCR) Score Threshold for Prognosticating Benefit From Multimodality Therapy. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 296-304.e3.	0.9	6
21	Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes. <i>European Urology</i> , 2021, 79, 141-149.	0.9	4
22	CCP score and risk stratification for prostate cancer patients at biopsy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 47-47.	0.8	4
23	Cell cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone. <i>Prostate</i> , 2021, 81, 261-267.	1.2	3
24	Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy. <i>Cancer Reports</i> , 2021, , e1535.	0.6	2
25	Predicting radical prostatectomy outcome: Cell cycle progression (CCP) score compared with primary Gleason grade among men with clinical Gleason less than 7 who are upgraded to Gleason 7.. <i>Journal of Clinical Oncology</i> , 2014, 32, 13-13.	0.8	2
26	Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing.. <i>Journal of Clinical Oncology</i> , 2015, 33, 64-64.	0.8	2
27	Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 366.e19-366.e28.	0.8	1
28	Validation of an active surveillance threshold for the CCP score in conservatively managed men with localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e16040-e16040.	0.8	1
29	Patient NCCN risk classification based on combined clinical cell cycle risk (CCR) score.. <i>Journal of Clinical Oncology</i> , 2017, 35, 249-249.	0.8	1
30	Ability of the combined clinical cell-cycle risk score to identify patients that benefit from multi versus single modality therapy in NCCN intermediate and high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 346-346.	0.8	1
31	In Reply to Berlin et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 240-241.	0.4	0
32	Association of the clinical cell-cycle risk score with metastasis after radiation therapy and identification of men with prostate cancer who can forgo combined androgen deprivation therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 195-195.	0.8	0
33	Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate- and high-risk prostate cancer overall, and in those who also received salvage radiotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 247-247.	0.8	0
34	Prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 17-17.	0.8	0
35	Cell cycle progression score to predict metastatic progression of clear cell renal cell carcinoma after resection.. <i>Journal of Clinical Oncology</i> , 2014, 32, 442-442.	0.8	0
36	Validation of an RNA cell cycle progression (CCP) score for predicting prostate cancer death in a conservatively managed needle biopsy cohort.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5059-5059.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Performance of CCP assay in an updated series of biopsy samples obtained from commercial testing.. Journal of Clinical Oncology, 2015, 33, 5033-5033.	0.8	0
38	Prognostic utility of a multi-gene signature (the cell cycle proliferation score) in patients with renal cell carcinoma (RCC) after radical nephrectomy.. Journal of Clinical Oncology, 2016, 34, 555-555.	0.8	0
39	Evaluation of microarrays for measuring cell cycle progression (CCP) gene expression.. Journal of Clinical Oncology, 2017, 35, e16566-e16566.	0.8	0
40	Outcomes of men with prostate cancer managed with active surveillance and tested with clinical cell-cycle risk score.. Journal of Clinical Oncology, 2019, 37, e16566-e16566.	0.8	0
41	Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate and high-risk prostate cancer.. Journal of Clinical Oncology, 2019, 37, e16575-e16575.	0.8	0
42	Cell cycle progression score differentiates indolent from aggressive prostate cancer in men diagnosed by TURP.. Journal of Clinical Oncology, 2019, 37, e16560-e16560.	0.8	0
43	Ability of cell-cycle progression score to predict risk for progression to metastatic disease and disease-specific mortality in prostate cancer patients after prostatectomy.. Journal of Clinical Oncology, 2020, 38, 5524-5524.	0.8	0
44	Renal biopsy cell cycle proliferation (CCP) score to predict adverse surgical pathology in renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 747-747.	0.8	0